用结局数据论证引入新技术:单中心经验
单中心回顾性分析347例2015年1月至2016年4月行结肠切除并一期吻合的患者,按术中是否使用荧光成像分层。PINPOINT组238例吻合失败2例(0.84%),非PINPOINT组109例失败6例(5.5%);PINPOINT组11例(4.6%)因荧光评估改变切除边界且均无吻合失败,作者认为减少吻合失败带来的直接成本下降可在143例后抵消新技术投入。
要点
- PINPOINT组吻合失败率0.84%(2/238),非PINPOINT组5.5%(6/109)
- PINPOINT组11例(4.6%)因荧光成像改变切除边界,均未发生吻合失败
- 作者称减少吻合失败的直接成本节省在143例后即可抵消购置新技术的支出
核心结论
- 荧光成像用于结直肠手术可降低结肠切除患者的吻合失败率,并因减少并发症相关直接成本而抵消新技术投入。
研究设计与样本
- 单中心回顾性分析,纳入2015年1月至2016年4月行结肠切除并一期吻合的全部患者347例,按术中是否使用荧光成像分层。
主要发现
- PINPOINT组238例中吻合失败2例(0.84%),非PINPOINT组109例中吻合失败6例(5.5%)。
- PINPOINT组11例(4.6%)依据荧光成像结果改变切除边界,这些患者均未发生吻合失败。
- PINPOINT组每例直接成本更低,原因在于并发症相关直接成本减少。
关键数值与推荐
- 原文报告PINPOINT组吻合失败率0.84%(2/238),非PINPOINT组5.5%(6/109)。
- 原文报告PINPOINT组11例(4.6%)因荧光成像改变切除边界,且均无吻合失败。
- 作者称减少吻合失败带来的直接成本节省在143例后即可抵消新技术购置费用。
临床怎么用
- 对结肠切除并一期吻合患者,可考虑术中荧光成像评估组织灌注以辅助决策切除边界。
- 引入新技术时可用本机构吻合失败率与直接成本数据测算投入回收所需病例数。
局限性
- 单中心回顾性设计,非随机分组,存在选择偏倚可能。
- 为单机构经验,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The PILLAR II trial demonstrated PINPOINT is safe, feasible to use with no reported adverse events and resulted in no anastomotic leaks in patients who had a change in surgical plan based on PINPOINT's intraoperative assessment of tissue perfusion during colorectal resection. Whether the cost savings associated with this reduction in anastomotic complications can offset the cost of investing in PINPOINT is unknown. METHODS: We performed a retrospective analysis of all patients (N = 347) undergoing colectomy with primary anastomosis from January 2015 to April 2016. These patients were stratified based on whether fluorescence imaging was used intraoperatively. The clinical outcomes of these patients were then evaluated based on their development of an anastomotic leak or stricture. The direct hospital costs per case were then calculated, and the economic impact of using fluorescence imaging was examined to assess whether decreased direct costs would justify the initial expenditures to purchase new technology (PINPOINT System, NOVADAQ, Canada). RESULTS: Fluorescence imaging in colorectal surgery using PINPOINT reduced the anastomotic failure rate in patients who underwent colon resection. The PINPOINT group (n = 238) had two (0.84%) anastomotic failures, while the non-PINPOINT group (n = 109) had six (5.5%) anastomotic failures. In the PINPOINT group, 11 (4.6%) patients had a change in the resection margin based on the results of the fluorescence imaging, and none of these patients experienced an anastomotic failure. Cost per case was less in the PINPOINT group secondary to fewer direct costs associated with complications. CONCLUSIONS: These results validate the findings of the PILLAR II trial and confirm the decrease in direct costs due to reduction in anastomotic failures as a result of using PINPOINT justified the expense of the new technology after just 143 cases.
引用
- Starker PM, Chinn B. Using outcomes data to justify instituting new technology: a single institution's experience. Surg Endosc. 2017. PMID: 29273871. doi:10.1007/s00464-017-6001-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。